Avalyn Pharma
AVLN28.1302.59% ( +0.710 )
Avalyn Pharma (AVLN)
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary f...
- Open
- 28.590
- High
- 28.920
- Low
- 27.720
- Prev. Close
- 27.420
- Volume
- 526.20K
- Turnover
- 14.87M
- Avg Price
- 28.257
- Bid/Ask Ratio
- --
- Amplitude
- 4.38%
- 52wk High
- 40.170
- Volume Ratio
- 2.15
- Turnover Ratio
- 2.09%
- 52wk Low
- 24.150
- Float Mkt Cap
- 706.77M
- Market CapUSD
- 1.25B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -2.33
- EPSDynamic
- -2.52
- EPSStatic
- --
- BVPS
- 8.99
- P/B
- 3.13
- Circulating Supply
- 25.13M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 44.33M
- Min lot size
- 1
- Currency
- USD
Avalyn Pharma Analyst Rating
View moreForecast & Rating
Oct 2, 2026Price forecast
$61.80119.69%
Forecast & RatingStrong buy
5analysts
- Strong buy60.00%
- Buy40.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article ·
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- PUBT ·
Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levels
- Unusual Whales ·
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
- Market Beat ·
Avalyn Pharma (NASDAQ:AVLN) Cut to "Sell" at Wall Street Zen
- PUBT ·
Avalyn Pharma Director Robert J. Meyer files initial beneficial ownership statement
- PUBT ·
Avalyn Pharma names former FDA leader Robert J. Meyer to board
